3sbio, Inc. · HKEX:1530
3sbio — H1 2023 Earnings Presentation
43 slides from 3sbio's earnings presentation, Aug 24, 2023
Slide 1: 2023 Interim Results Presentation
2023 Interim Results Presentation 24 August, 2023
Slide 2: Disclaimer
Disclaimer This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only. You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") befor
Slide 3: Agenda
Agenda 01 02 03 04 05 Business R&D Financial Highlights Q&A Overview Review 3
Slide 4: Chairman, Director & CEO Dr. Jing LOU
Chairman, Director & CEO Dr. Jing LOU
Slide 5: 2023H1 Financial Highlights
2023H1 Financial Highlights Biopharmaceuticals Main Performance 2023H1 2022H1 YoY (RMB Mn) Revenue increased by 20% to 2909 mn RMB, 4 core products covered nephrology, autoimmune, hematology, oncology etc. Revenue 3783.8 3,094.5 22.3% Hair Healthiness Revenue increased by 36% to 508 mn RMB, Gross Pr
Slide 6: Improve ESG Governance Continuously
Improve ESG Governance Continuously • Take social responsibilities , devote to public welfare actively • Support“Ankylosing Spondylitis Healthy Village Program”, Aided and treated cumulative thousands of patients in AS, cancer, dialysis etc. • ESG governance rated AA by MSCI, exceeding 88% biotech c
Slide 7: Chairman, Director & CEO Dr. Jing LOU
Chairman, Director & CEO Dr. Jing LOU
Slide 8: Biopharmaceuticals
Biopharmaceuticals
Slide 9: TPIAO- Global Exclusive Commercialized rhTPO
TPIAO- Global Exclusive Commercialized rhTPO Revenue of TPIAO, 2023H1 Top 1 market share 1 65% 1 market share in terms of sales, still tops the first position in rhTPO products RMB Mn 64.6% YOY：28.2% TPIAO 3,397 Interleukin-11 3,080 2,763 2,019 1,575 Oral TPO-RA 2020 2021 2022 2022H1 2023H1 1.Data s
Slide 10: TPIAO- Clinical Studies Advance Indication Expansion
TPIAO- Clinical Studies Advance Indication Expansion Children or adolescents Chronic liver Chemotherapy induced Primary immune with chronic primary Bone marrow thrombocytopenia thrombocytopenia Immune disease related protection form thrombocytopenia thrombocytopenia (CIT) (ITP) (Pediatric ITP) acute
Slide 11: rhEPO- EPIAO & SEPO
rhEPO- EPIAO & SEPO Revenue of rhEPO, 2023H1 TOP 1 Market share 1 Two brands dominate 43%1 market share, preside Top 1 position in terms of EPO market share RMB Mn • EPIAO® quality standard is consistent with EU Pharmacopeia YOY：-13.1% • Revenue from Non-VBP provinces shows positive growth, with a s
Slide 12: Yisaipu- Explore to Reform
Yisaipu- Explore to Reform Revenue of Yisaipu, 2023H1 RMB Mn Demands rebound to growth • The treatment demands for chronic diseases have returned to normal YOY：25.0% Expand new formulation • Pre-filled injection got approval and marketed in May 2023 804 630 531 Persistent foundation work 304 • Promo
Slide 13: Cipterbin- Provide More Choice for Patients
Cipterbin- Provide More Choice for Patients Revenue of Cipterbin, 2023H1 HER2-positive advanced breast cancer H treatment Grade I recommendations Grade I recommendations: (1) THP (IA); (2) TXH (2A) --Anti-HER2 mAb (H), including commercialized Trastuzumab, RMB Mn biosimilars, Inetetamab YOY：60.5% 20
Slide 14: Hair Healthcare
Hair Healthcare
Slide 15: Mandi – Effective & Reliable Hair Growth Drug
Mandi – Effective & Reliable Hair Growth Drug Revenue of Mandi, 2023H1 Top 1 Market Share 1 70% market share in medical institutions, secured Top 1 among all minoxidil 1 RMB Mn 70.3% YOY：35.8% Mandi Product A 891 Product B 602 498 others 368 367 2020 2021 2022 2022H1 2023H1 1. Data source of market
Slide 16: Target at Consumption, Digital Marketing Lead Brand Growth
Target at Consumption, Digital Marketing Lead Brand Growth Scientific and effective hair growth choice wins more recognition • Education to enhance • Release female customer • Minoxidil, as a scientific, effective safe and convenient hair growth the recognition of purchasing power from product, its
Slide 17: Mandi- Build Product Matrix, Expand Brand Value
Mandi- Build Product Matrix, Expand Brand Value Enrich Mandi matrix Mandi Comb Mandi (60mL, 90mL) Mandi White Bottle Mandi Mandi White Bottle 01 60/90mL 02 30mL female monthly Male monthly pack/ pack, quantitative use treatment course pack Mandi Pro Mandi Shampoo Mandi Shampoo Mandi Pro 03 10mL mini
Slide 18: CDMO
CDMO
Slide 19: Domestic CDMO Pioneer
Domestic CDMO Pioneer Revenue of CDMO, 2023H1 RMB Mn Overseas 109 Mn China 57 Mn 29% YOY 246% YOY 57 Mn 38 Mn 44 Mn YOY：71.6% 11 Mn 166 106 111 95 55 2020 2021 2022 2022H1 2023H1 92% revenue from 27 new orders 75% customer 160 Mn commercialized orders signed in 2023H1 retention rate backlogs 19
Slide 20: Differentiation Advantages Support Clients
Differentiation Advantages Support Clients • 4 plants, providing comprehensive biopharmaceutical R&D service and SIGO equipping with manufacture capabilities Disposable + stainless flexible capabilities; provide professional Biopharmaceuticals Formulations GCT biopharmaceutical CDMO service Culture
Slide 21: Chairman, Director & CEO Dr. Jing LOU
Chairman, Director & CEO Dr. Jing LOU
Slide 22: R&D Pipeline
R&D Pipeline Therapeutic Area Candidates Pre-clinical IND Phase I Phase II Phase III NDA 3 SSS06 Long-acting rhEPO Pre-clinical RD01 Long-acting rhEPO Nephrology SSS12 Cinacalcet hydrochloride ANDA TRK-820 Liver Disease Pruritus SSS17 HIF inhibitor TPO-105 Pediatric ITP NDA 5 TPO-106 CLDT IND& phase
Slide 23: Key Candidates- Nephrology
Key Candidates- Nephrology Remitch® 5 Candidates • Around dialysis and its complication Narfuraphine hydrochloride orally disintegrating tablets Remitch Narfuraphine hydrochloride orally disintegrating tablets 1st and Exclusive commercialized domestic CKD pruritus (Chronic liver disease induced prur
Slide 24: Key Candidates- Hematology /Oncology
Key Candidates- Hematology /Oncology Explore New Indication TPIAO: 130K /year new pediatric ITP patients1 and 350K+ CLDT patients2 , clinical studies prove safety and efficacy TPO-105 Pediatric ITP Cipterbin: explore applications in Her2- positive breast cancer neoadjuvant, cover more breast cancer
Slide 25: Key Candidates- Autoimmune
Key Candidates- Autoimmune Focus on Chinese Autoimmune Wide Market Dermatology Rheumatism 45 Mn 24 Mn 608 anti-IL-17A mAb Moderate-to-severe plaque psoriasis (PsO) Phase III 613 anti-IL-1β mAb Acute gouty arthritis Phase II 610 anti-IL-5 mAb Severe eosinophilic asthma Respiratory Phase II 14 Mn 611
Slide 26: Key Candidates- Dermatology
Key Candidates- Dermatology First new mechanism of action in acne The most prescribed branded topical acne 1st • approved by the FDA in 40 years Winlevi® is the global 1st external topical androgen receptor inhibitor developed by Cosmo for the acne vulgaris in patients 12 years and older, and was ap
Slide 27: Marketing Outlook and Peak Sales Expectation
Marketing Outlook and Peak Sales Expectation Winlevi 601A (acne) (anti-VEGF mAb) Autoimmune Est. NDA 608 613 610 key candidates submission (anti-IL-17mAb) (anti-IL-1βmAb) (anti-IL-5 mAb) SSS06 Remitch 611 (long-acting EPO) (liver disease pruritus) (anti-IL-4R mAb) 608 (IL-17A) Moderate-to-severe 202
Slide 28: 608 (Anti-IL17A mAb)
608 (Anti-IL17A mAb) Phase II data shows specific efficacy in PsO patients Week 12 primary endpoint data of 608, Secukinumab, Ixekizumab in PsO patients • Week 12 Data shows the efficacy of 608 at different doses is much better than placebo group & launched products 93.4 *** 96.43 100. 93.55 * 92.86
Slide 29: 613 (Anti IL1β mAb)
613 (Anti IL1β mAb ) Acute gouty arthritis Phase II study met primary endpoint Recurrence rate of acute gout in 12 weeks was significantly • Effect begins 6 Hrs after administration lower than control group 16/31 • 613 performed better in reducing pain with time Patients with acute gout recurrence M
Slide 30: 611 (Anti IL-4R mAb)
611 (Anti IL-4R mAb ) AD Phase II shows better performance than control • Data from Week shows 611 has better IGA declined ≥2 from baseline performance than Dupilumab on EASI-75 and IGA 0/14 and NRS 46.7% declined ≥2 from baseline 41.9% 33.3% 35.5% EASI 752 IGA 0 /1 EASI 50 NRS ≥43 Group A1 12.5% 9.
Slide 31: 610 (Anti-IL5 mAb)
610 (Anti-IL5 mAb) Significantly Improve the pulmonary function of severe asthma patients The analysis of phase Ib blinding clinical trial shows FEV1 is enhanced • Progress ranks NO.1 in China 0.45 0.424 Company Code Indication 0.4 0.35 SSGJ SSGJ-610 Phase II in eosinophil asthma is in recruitment 0
Slide 32: SSS06 (Long-acting rhEPO)
SSS06 (Long-acting rhEPO) Phase II clinical trial data indicate safety and efficacy rhEPO VS SSS06 clinical efficacy data: rhEPO rESA QW rESA QOW • 2nd-generation EPO， extend half -life for (Screening Dose) （0.5ug/kg） （1.0ug/kg） 2 weeks dosing intervals, match treatment cycles of chemotherapy patien
Slide 33: 601A (anti-VEGF mAb)
601A (anti-VEGF mAb) BRVO phase II clinical trial data shows significant efficacy • W24 data indicates better trend of 601A primary Eyes differences FAS of BCVA versus baseline and key efficacy than ranibizumab during 52 weeks study period 601A trial group (n=31) Ranibizumab control group (n=29) Ran
Slide 34: 602 (anti-EGFR mAb)
602 (anti-EGFR mAb) Phase II trial in mCRC First-line treatment shows significant efficacy 602 Q2W group 602 QW group Erbitux group N=28(%) N=31(%) N=14(%) Best overall response rate 22 (78.6) 26 (83.9) 10 (71.4) BIRC (Independent Complete response rate (CR) 0 1 (3.2) 0 review Partial response rate
Slide 35: Chief Financial Officer Mr. Tony HE
Chief Financial Officer Mr. Tony HE
Slide 36: Financial Analysis
Financial Analysis Revenue Gross Profit NI Attributable to Parent Norm NI Attributable to Parent 22.3 % YOY 24.8 % YOY 1.4% YOY 20.1 % YOY RMB Bn RMB Bn RMB Mn RMB Mn 6.9 2,164 6.4 1,915 5.6 1,651 1,727 5.7 5.3 3.8 4.5 1,166 1,191 967 981 3.1 992 3.2 836 2.6 36
Slide 37: Expense Ratio Declined
Expense Ratio Declined Selling and Distribution Expenses R&D Costs Administrative Expenses RMB Bn RMB Mn RMB Mn 2.6 800 754 2.3 693 700 2.0 590 600 500 500 435 1.4 385 400 400 371 1.2 294 307 300 300 198 214 200 200 100 100 0 0 0 2020 2021 2022 2022H1 2023H1 2020 2021 2022 2022H1 2023H1 2020 2021 20
Slide 38: Maintain Stable Asset Structure
Maintain Stable Asset Structure Total Assets Net Assets Debt Asset Ratio RMB Bn RMB Bn 31% 30% 30% 26% 24% 20 22.0 23.2 19.2 17.7 14.8 15.4 16.0 14.7 13.1 10.4 2019 2020 2021 2022 2023H1 0 2019 2020 2021 2022 2023H1
Slide 39: Sublime CF Condition, Sufficient FCF
Sublime CF Condition, Sufficient FCF Cash Equivalents (Financing Proceeds included) OCF 15.3 % YOY RMB Bn RMB Bn 7.4 7.4 1.6 1.3 5.0 1.2 1.2 4.5 1.0 2.6 2020 2021 2022 2022H1 2023H1 2019 2020 2021 2022 2023H1 1：Funds stock including cash and cash equivalents, Non-pledged time deposits with original
Slide 40: Extremely Attractive Earnings
Extremely Attractive Earnings EPS (RMB) ROE 2.6 % YOY RMB 12.4% 12.4% 0.78 11.1% 0.65 9.5% 0.39 0.4 5.9% 0.33 2020 2021 2022 2022H1 2023H1 2019 2020 2021 2022 2023H 40
Slide 41: Sustain Robust Growth, Repay Shareholders
Sustain Robust Growth, Repay Shareholders Net Income attributable to parent 5 years of CAGR 10.7% TPIAO Cipterbin Mandi R&D Robust Exclusive First-line Drug New Launch Performance Top 1 Brand Product Improve clinical Deliver sustainable Successful NRDL Advanced penetration rate, 3 new drugs marketed
Slide 42: Management Team
Business Overview fre Go » wu YY ey ae ey h, a Financial : UE dy Review rd
Slide 43: THANKS
THANKS 3SBio Inc. (1530.HK) Investor Relations ir@3sbio.com 珍 爱 生 命 · 关 注 生 存 · 创 造 生 活 CHERISH LIFE CARE FOR LIFE CREATE LIFE